Explore

Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases
Trendline Trendline
AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics
Trendline Trendline
Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI
Trendline Trendline
Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement
Trendline Trendline
Cellular Intelligence Licenses Novo Nordisk's Parkinson's Cell Therapy for AI-Enhanced Development

Cellular Intelligence Licenses Novo Nordisk's Parkinson's Cell Therapy for AI-Enhanced Development

Cellular Intelligence Licenses Novo Nordisk's Parkinson's Cell Therapy for AI-Enhanced Development
Trendline Trendline
Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences

Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences

Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases